# Natriuretic Effect of Amiloride in Relation to the Alpha Adducin Gene (ADD-AMI) RS4961 Variant

> **NCT06416735** · PHASE3 · COMPLETED · sponsor: **Ospedale San Raffaele** · enrollment: 40 (actual)

## Conditions studied

- Hypertension Essential
- Salt Excess
- Genetic Hypertension

## Interventions

- **DRUG:** Amiloride

## Key facts

- **NCT ID:** NCT06416735
- **Lead sponsor:** Ospedale San Raffaele
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-28
- **Primary completion:** 2020-07-20
- **Final completion:** 2020-07-20
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06416735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06416735, "Natriuretic Effect of Amiloride in Relation to the Alpha Adducin Gene (ADD-AMI) RS4961 Variant". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06416735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*